Wegovy is a prescription medication used to treat obesity. It contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps to regulate blood sugar levels and reduce appetite. According to the official Wegovy website [2], the recommended dosage of Wegovy is 2.4 mg, administered once a week. The medication is administered subcutaneously (under the skin) and should be taken on the same day each week. It is important to follow the dosing schedule recommended by your healthcare provider.

The recommended dosage of Wegovy is consistent with the dosage approved by the FDA [1]. The FDA approval is based on clinical trials that demonstrated the efficacy and safety of Wegovy in reducing body weight in obese individuals.

It is important to note that Wegovy should only be used under the guidance of a healthcare provider. The medication is not recommended for use in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Additionally, the medication may interact with other medications, so it is important to inform your healthcare provider of all medications you are taking before starting Wegovy [3].

In summary, the recommended dosage of Wegovy is 2.4 mg, administered once a week. It is important to follow the dosing schedule recommended by your healthcare provider and to only use the medication under their guidance.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://www.wegovy.com/taking-wegovy/dosing-schedule.html
[3] https://www.drugs.com/dosage/wegovy.html